|
|
Session 8: Optimize the Development and Review Processes for New Cancer Drugs (Part I) |
Session Chair: Dr. Gary T Wang, Associate Research Fellow, Cancer Research, Abbott Laboratories, USA
Co-Chair: Dr. Blanka Rihova, Director, The Institute of Microbiology, Academy of Sciences, The Czech Republic |
|
|
Title: Anti-cancer Drug Discovery
Dr. Gary T Wang, Associate Research Fellow, Cancer Research, Abbott Laboratories, USA |
|
Title: Immunomodulating Polymer-based Nanotherapeutics with Cytostatic Activity
Dr. Blanka Rihova, Director, the Institute of Microbiology, Academy of Sciences, The Czech Republic |
|
Title: Antagonists of IAPs for Anticancer Therapy: A Structure-based Drug Discovery Approach to a Protein-protein Interaction Target
Dr. Zhuoliang (Julian) Chen, Senior Research Investigator, Novartis Institutes for BioMedical Research, Inc., Global Discovery Chemistry, USA
|
|
Title: Efficient Anticancer Drugs Have Promiscous Mechanisms of Action
Dr. Stig Linder, Professor of Experimental Oncology, Cancer center Karolinska, Department of Oncology-Pathology, Karolinska Institute, Sweden
|
|
Title: Developing Novel Drug Molecules That Target Epigenetic Enzymes
Dr. Yujun George Zheng, Department of Chemistry, Georgia State University, USA |
|
Title: New Drug Target I. T-type Ca2+ Channels
Dr. Ming Li, Associate Professor of Pharmacology & Physiology, Physiology, Tulane University Health Sciences Center, USA
|
|
Title: Tumor Cell-Specific Nuclear Targeting
Dr. David A. Jans, Nuclear Signalling Laboratory, Department of Biochemistry and Molecular Biology, Monash University, Australia
|
|
Title: Aurora Kinases and Their Inhibitors: More than One Target and One Drug
Dr. J¨¹rgen Moll, Director Cell Biology Department of Nerviano Medical Sciences Srl., Italy
|
|
Title: Inhibition of the Extracelluar Matrix of the Tumor Microenvironment as a Novel Strategy for Cancer Treatment, Effect of Halofuginone
Dr. Mark Pines, Senior Scientist, Institute of Animal Sciences, Agricultural Research Organization, Israel |
|
